These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12538930)

  • 21. Monitoring response to treatment in the development of anticancer drugs using PET.
    Price P
    Nucl Med Biol; 2000 Oct; 27(7):691. PubMed ID: 11091114
    [No Abstract]   [Full Text] [Related]  

  • 22. New horizons in oncologic imaging.
    Koh DM; Cook GJ; Husband JE
    N Engl J Med; 2003 Jun; 348(25):2487-8. PubMed ID: 12815132
    [No Abstract]   [Full Text] [Related]  

  • 23. [Positron emission tomography in the Netherlands: need to expand the capacity].
    Comans EF; Smit EF
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1817-9. PubMed ID: 12382364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case report. FDG-PET in occult breast cancer].
    Ladjevardi S; Sörensen J; Hellman P; Juhlin C; Wärnberg F
    Lakartidningen; 2002 Feb; 99(6):524-6. PubMed ID: 11881227
    [No Abstract]   [Full Text] [Related]  

  • 25. [Positron emission tomography in oncology].
    Hatazawa J; Higuchi I; Nakamura H
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):748-54. PubMed ID: 12852339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer.
    Siegel BA; Adler LP; Wahl RL
    AJR Am J Roentgenol; 2002 Mar; 178(3):762-4. PubMed ID: 11856715
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic drug monitoring in oncology: does it have a future?
    McMahon G; O'Connor R
    Bioanalysis; 2009 Jun; 1(3):507-11. PubMed ID: 21083145
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic Drug Monitoring in Oncology.
    Wilkinson DS
    Ther Drug Monit; 2019 Oct; 41(5):551-552. PubMed ID: 31318845
    [No Abstract]   [Full Text] [Related]  

  • 29. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early experience with PET scanning in thoracic tumours.
    Kutlu CA; Pastorino U; Maisey M; Goldstraw P
    J Cardiovasc Surg (Torino); 2001 Jun; 42(3):403-7. PubMed ID: 11398041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography and colorectal carcinoma: an update.
    Tzimas GN; Koumanis DJ; Meterissian S
    J Am Coll Surg; 2004 Apr; 198(4):645-52. PubMed ID: 15051018
    [No Abstract]   [Full Text] [Related]  

  • 32. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
    Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET: other thoracic malignancies.
    Quint LE
    Cancer Imaging; 2006 Oct; 6(Spec No A):S82-8. PubMed ID: 17114082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of imaging in the development of oncologic agents.
    Shields AF; Ho PT; Grierson JR
    J Clin Pharmacol; 1999 Aug; 39(S1):40S-44S. PubMed ID: 10434247
    [No Abstract]   [Full Text] [Related]  

  • 35. FDG positron emission tomography for evaluating breast cancer.
    TEC Bull (Online); 2003 Nov; 20(3):1-7. PubMed ID: 15043076
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
    Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
    J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET in staging lung cancer: how does it change the algorithm?
    Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
    Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
    Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unusually high uptake of fluoro-2-deoxy-D-glucose on PET scanning of a benign paravertebral mass.
    Doss M
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):310-1. PubMed ID: 9477465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved image interpretation with registered thoracic CT and positron emission tomography data sets.
    Aquino SL; Asmuth JC; Moore RH; Weise SB; Fischman AJ
    AJR Am J Roentgenol; 2002 Apr; 178(4):939-44. PubMed ID: 11906878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.